Navigation Links
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA
Date:11/6/2008

SAN FRANCISCO, Nov. 6 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it will hold a conference call and webcast to discuss results of the VIA-2291 Phase 2 acute coronary syndrome (ACS) and carotid endarterectomy (CEA) trials presented at the American Heart Association (AHA) Scientific Sessions 2008 on Sunday, November 9. The conference call and webcast will take place on Monday, November 10, at 8:30 a.m. ET (7:30 a.m. CT).

To participate in the conference call, please dial 888-684-1280 for domestic callers and 913-312-0952 for international callers. A telephone replay of the conference call will be available through Friday, November 14, 2008. To access the replay, please dial 888-203-1112 for domestic callers and 719-457-0820 for international callers and reference conference replay passcode 1268443.

In addition, interested parties may access a live audio webcast of the presentation from the investor section of the VIA website, http://www.viapharmaceuticals.com. A replay of the presentation will be archived on the VIA website for 30 days following the presentation.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.


'/>"/>
SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
2. Raptor Pharmaceuticals Provides Update on Targeting Platforms
3. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
4. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
5. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
6. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
7. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
8. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
9. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415
10. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
11. Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Research and Markets has announced the addition of ... to 2025" report to their offering. ... The Global Cryostat Market is poised ... decade to reach approximately $3.5 billion by 2025. This ... given segments on global as well as regional levels presented in ...
(Date:3/23/2017)... March 23, 2017 Mosaic Life Care, based in St. Joseph, ... process across its network of 58 clinics, located in 22 cities, and its flagship ... innovative ways to improve the delivery of health care to its patients, including the ... ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... , March 23, 2017 The ... ageing population, increasing diabetic population, accelerating economic growth and increasing ... this industry are higher life expectancy of ESRD patients, rising ... emerging markets. However, the expansion of the market is hindered ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... After raising more than $1.135 million ($1,479,231 AUD) from ... pillow in crowdfunding history, has established a U.S. Headquarters in New York City, ... Americans. , “We’re excited to be operating on U.S. shores, where most of our ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... for seniors, today announced rapid completion of the strategic executive team expansion needed ... notable additions to the ChenMed executive team,” says Christopher Chen, MD, ChenMed Chief ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... Monitoring Healthcare products at competitive pricing. Verisys through its FACIS ... Debarments, License restrictions and Disciplinary actions. , “We are delighted to be able ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... and non-steroidal skincare products, was awarded as winners of American Dreams & Good ... competition was hosted jointly by HSN and Good Housekeeping. , Steven Wang, ...
Breaking Medicine News(10 mins):